Characterization of a Peptide Domain Within the GB Virus C Envelope Glycoprotein (E2) That Inhibits HIV Replication

Overview

Journal Virology

Specialty Microbiology

Date 2012 May 22

PMID 22608061

Citations 13

Authors

Jinhua Xiang

James H McLinden

Thomas M Kaufman

Emma L Mohr

Nirjal Bhattarai

Qing Chang

Jack T Stapleton

Affiliations

Soon will be listed here.

Abstract

GB virus C (GBV-C) infection is associated with prolonged survival in HIV-infected cohorts, and GBV-C E2 protein inhibits HIV entry when added to CD4+ T cells. To further characterize E2 effects on HIV replication, stably transfected Jurkat cell lines expressing GBV-C E2 or control sequences were infected with HIV and replication was measured. HIV replication (all 6 isolates studied) was inhibited in all cell lines expressing a region of 17 amino acids of GBV-C E2, but not in cell lines expressing E2 without this region. In contrast, mumps and yellow fever virus replication was not inhibited by E2 protein expression. Synthetic GBV-C E2 17mer peptides did not inhibit HIV replication unless they were fused to a tat-protein-transduction-domain (TAT) for cellular uptake. These data identify the region of GBV-C E2 protein involved in HIV inhibition, and suggest that this GBV-C E2 peptide must gain entry into the cell to inhibit HIV.

Citing Articles

Human Pegivirus Type 1: A Common Human Virus That Is Beneficial in Immune-Mediated Disease?.

Stapleton J Front Immunol. 2022; 13:887760.

PMID: 35707535 PMC: 9190258. DOI: 10.3389/fimmu.2022.887760.

Development of peptide inhibitors of HIV transmission.

Shi S, Nguyen P, Cabral H, Diez-Barroso R, Derry P, Kanahara S Bioact Mater. 2018; 1(2):109-121.

PMID: 29744399 PMC: 5883972. DOI: 10.1016/j.bioactmat.2016.09.004.

Yellow Fever Virus, but Not Zika Virus or Dengue Virus, Inhibits T-Cell Receptor-Mediated T-Cell Function by an RNA-Based Mechanism.

McLinden J, Bhattarai N, Stapleton J, Chang Q, Kaufman T, Cassel S J Infect Dis. 2017; 216(9):1164-1175.

PMID: 28968905 PMC: 5853456. DOI: 10.1093/infdis/jix462.

GB virus type C E2 protein inhibits human immunodeficiency virus type 1 Gag assembly by downregulating human ADP-ribosylation factor 1.

Wang C, Timmons C, Shao Q, Kinlock B, Turner T, Iwamoto A Oncotarget. 2015; 6(41):43293-309.

PMID: 26675377 PMC: 4791233. DOI: 10.18632/oncotarget.6537.

Conserved Motifs within Hepatitis C Virus Envelope (E2) RNA and Protein Independently Inhibit T Cell Activation.

Bhattarai N, McLinden J, Xiang J, Kaufman T, Stapleton J PLoS Pathog. 2015; 11(9):e1005183.

PMID: 26421924 PMC: 4589396. DOI: 10.1371/journal.ppat.1005183.

References

Xiang J, George S, Wunschmann S, Chang Q, Klinzman D, Stapleton J . Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet. 2004; 363(9426):2040-6. DOI: 10.1016/S0140-6736(04)16453-2. View

Lindenbach B, Rice C . Molecular biology of flaviviruses. Adv Virus Res. 2003; 59:23-61. DOI: 10.1016/s0065-3527(03)59002-9. View

Dawson G, Schlauder G, Thiele D, Leary T, Murphy P, Rosenblatt J . Prevalence studies of GB virus-C infection using reverse transcriptase-polymerase chain reaction. J Med Virol. 1996; 50(1):97-103. DOI: 10.1002/(SICI)1096-9071(199609)50:1<97::AID-JMV16>3.0.CO;2-V. View

Jung S, Knauer O, Donhauser N, Eichenmuller M, Helm M, Fleckenstein B . Inhibition of HIV strains by GB virus C in cell culture can be mediated by CD4 and CD8 T-lymphocyte derived soluble factors. AIDS. 2005; 19(12):1267-72. DOI: 10.1097/01.aids.0000180097.50393.df. View

Linnen J, Wages Jr J, FRY K, Krawczynski K, Alter H, Koonin E . Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science. 1996; 271(5248):505-8. DOI: 10.1126/science.271.5248.505. View

van der Bij A, Kloosterboer N, Prins M, Boeser-Nunnink B, Geskus R, Lange J . GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study. J Infect Dis. 2005; 191(5):678-85. DOI: 10.1086/427559. View

Carrick R, COLEMAN P, Leary T, Surowy T, Simons J, Muerhoff A . Expression of the GB virus C E2 glycoprotein using the Semliki Forest virus vector system and its utility as a serologic marker. Virology. 1996; 225(2):282-92. DOI: 10.1006/viro.1996.0602. View

Kim J, FRY K . Molecular characterization of the hepatitis G virus. J Viral Hepat. 1997; 4(2):77-9. DOI: 10.1111/j.1365-2893.1997.tb00208.x. View

Alter M, Gallagher M, Morris T, Moyer L, Meeks E, Krawczynski K . Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. Sentinel Counties Viral Hepatitis Study Team. N Engl J Med. 1997; 336(11):741-6. DOI: 10.1056/NEJM199703133361101. View

10.

Rey D, Meyer P, Schmitt C, Fritsch S, Lang J, Stoll-Keller F . High prevalence of GB virus C/hepatitis G virus RNA and antibodies in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis. 2000; 19(9):721-4. DOI: 10.1007/s100960000352. View

11.

Xiang J, McLinden J, Chang Q, Jordan E, Stapleton J . Characterization of a peptide domain within the GB virus C NS5A phosphoprotein that inhibits HIV replication. PLoS One. 2008; 3(7):e2580. PMC: 2440355. DOI: 10.1371/journal.pone.0002580. View

12.

Krey T, dAlayer J, Kikuti C, Saulnier A, Damier-Piolle L, Petitpas I . The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog. 2010; 6(2):e1000762. PMC: 2824758. DOI: 10.1371/journal.ppat.1000762. View

13.

Alter H, Nakatsuji Y, Melpolder J, Wages J, Wesley R, Shih J . The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med. 1997; 336(11):747-54. DOI: 10.1056/NEJM199703133361102. View

14.

Tillmann H, Heringlake S, Trautwein C, Meissner D, Nashan B, Schlitt H . Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus C de novo infection. Hepatology. 1998; 28(2):379-84. DOI: 10.1002/hep.510280213. View

15.

Thomas D, Vlahov D, Alter H, Hunt J, Marshall R, Astemborski J . Association of antibody to GB virus C (hepatitis G virus) with viral clearance and protection from reinfection. J Infect Dis. 1998; 177(3):539-42. DOI: 10.1086/514245. View

16.

Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H . Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. J Virol. 2011; 85(14):7037-47. PMC: 3126597. DOI: 10.1128/JVI.02366-10. View

17.

Rydze R, Bhattarai N, Stapleton J . GB virus C infection is associated with a reduced rate of reactivation of latent HIV and protection against activation-induced T-cell death. Antivir Ther. 2012; 17(7):1271-9. PMC: 3709856. DOI: 10.3851/IMP2309. View

18.

Jung S, Eichenmuller M, Donhauser N, Neipel F, Engel A, Hess G . HIV entry inhibition by the envelope 2 glycoprotein of GB virus C. AIDS. 2007; 21(5):645-7. DOI: 10.1097/QAD.0b013e32803277c7. View

19.

Mohr E, Stapleton J . GB virus type C interactions with HIV: the role of envelope glycoproteins. J Viral Hepat. 2009; 16(11):757-68. PMC: 3543829. DOI: 10.1111/j.1365-2893.2009.01194.x. View

20.

Heuft H, Berg T, Schreier E, Kunkel U, Tacke M, Schwella N . Epidemiological and clinical aspects of hepatitis G virus infection in blood donors and immunocompromised recipients of HGV-contaminated blood. Vox Sang. 1998; 74(3):161-7. View